Mefloquine Hcl (mefloquine HCl)

In the US, dosage of mefloquine hydrochloride is expressed in terms of the salt. Each 250-mg tablet of mefloquine hydrochloride commercially available in the US is equivalent to 228 mg of mefloquine base. Other formulations (e.g., 275-mg mefloquine hydrochloride tablets containing 250 mg of the base) may be available in other countries.

Dosage of mefloquine hydrochloride in children is based on body weight.

The manufacturer makes no specific recommendations regarding the need for dosage adjustment in individuals with renal impairment. When mefloquine is used for malaria prophylaxis, limited data indicate that dosage adjustment is not necessary in individuals undergoing hemodialysis.

The manufacturer makes no specific recommendations regarding the need for dosage adjustment in individuals with hepatic impairment. Pharmacokinetic data indicate that elimination of mefloquine may be prolonged and plasma concentrations may be increased in patients with impaired hepatic function. (See Other Precautions and Contraindications under Cautions: Precautions and Contraindications.)

Mefloquine hydrochloride is administered orally with ample water (at least 8 oz (240 mL) of water for an adult).

The drug should not be administered on an empty stomach.

If a patient receiving mefloquine for the treatment of malaria vomits within 30 minutes after receiving a dose of the drug, another full dose should be administered as a replacement; if a patient vomits within 30-60 minutes after receiving a dose, 50% of the dose should be administered as a replacement. If vomiting recurs, the patient should be monitored closely and alternative malaria treatment considered if improvement is not observed within a reasonable period of time.

For administration in children and others who are unable to swallow tablets, mefloquine hydrochloride tablets may be crushed and mixed with a small amount of liquid (e.g., water, milk, other beverage).

When mefloquine hydrochloride doses less than 125 mg (less than one-half of a 250-mg tablet) are indicated for pediatric patients, gelatin capsules containing the calculated pediatric dosage should be prepared extemporaneously by a pharmacist using a crushed tablet.

A mefloquine hydrochloride medication guide has been developed to help individuals understand the risks of malaria, risks and benefits of taking mefloquine to prevent malaria, and the rare but potentially serious adverse effects associated with use of the drug. As required by law, a copy of the mefloquine medication guide must be supplied to patients each time mefloquine is dispensed for prevention of malaria; an information wallet card also is supplied to the patient when the drug is dispensed.

Interactions between mefloquine and many other drugs, including cardiac drugs, have not been systematically evaluated. When mefloquine is used for prevention or chemoprophylaxis of malaria in travelers, possible effects of mefloquine on other drugs these individuals are receiving (especially anticoagulants and antidiabetic agents) should be assessed prior to departure.

Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

Antimalarial Agents/Penicillamine

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Concurrent use may result in additive or synergistic effects on the blood and kidneys(1) or increased penicillamine levels.(2)

CLINICAL EFFECTS: Concurrent use of penicillamine with antimalarials may result in serious hematologic or renal toxicity(1,2) or elevated levels of penicillamine.(2)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of penicillamine states that penicillamine should not be used in patients receiving concurrent therapy with antimalarial agents.(1)

DISCUSSION: In patients with rheumatoid arthritis, concurrent chloroquine increased penicillamine plasma concentrations by 34% when compared to penicillamine alone.(2) In a 2-year controlled, double-blind trial of penicillamine, hydroxychloroquine, or combination therapy, patients on combination therapy did not do as well as patients receiving penicillamine alone.(3) Because antimalarial agents are associated with hematologic and renal toxicity, the manufacturer of penicillamine states that penicillamine should not be used in patients receiving concurrent antimalarials.(1)

Antimalarials/Artemether; Lumefantrine

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Halofantrine and quinine may inhibit the metabolism of lumefantrine by CYP2D6.(1) The combination of artemether-lumefantrine and antimalarials may result in additive effects on the QT interval.(1)

CLINICAL EFFECTS: Concurrent use may result in toxicity and/or prolongation of the QT interval, which may result in life-threatening arrhythmias.(1,2)

PREDISPOSING FACTORS: The risk of QT prolongation or torsades de pointes may be increased in patients with cardiovascular disease (e.g. heart failure, myocardial infarction, history of torsades de pointes, congenital long QT syndrome), hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, female gender, or advanced age.(3) Concurrent use of more than one drug known to cause QT prolongation or higher systemic concentrations of either QT prolonging drug are additional risk factors for torsades de pointes. Factors which may increase systemic drug concentrations include rapid infusion of an intravenous dose or impaired metabolism or elimination of the drug (e.g. coadministration with an agent which inhibits its metabolism or elimination, genetic impairment in drug metabolism or elimination, and/or renal/hepatic dysfunction).(3)

PATIENT MANAGEMENT: The UK manufacturer of artemether-lumefantrine states that the concurrent use of artemether-lumefantrine with other antimalarials is contraindicated.(1) The US manufacturer of artemether-lumefantrine states that artemether-lumefantrine should not be given concurrently with antimalarials.(2) If a patient deteriorates during artemether-lumefantrine therapy and requires another antimalarial agent, it may be started immediately, but the UK manufacturer of artemether-lumefantrine recommends ECG and potassium monitoring.(1) In patients who have previously received halofantrine, both the UK and US manufacturers of artemether-lumefantrine recommends that one month elapse between the last dose of halofantrine and the initiation of artemether-lumefantrine.(1) If concurrent therapy is deemed medically necessary, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, or fainting.

DISCUSSION: In a study in 14 healthy subjects, administration of a single intravenous dose of quinine (10 mg/kg) 2 hours after the sixth dose of artemether-lumefantrine had no effect on lumefantrine or dihydroartemisinin levels. Artemether levels were decreased; however, this was not believed to be clinically significant.(1,2) Concurrent quinine and artemether-lumefantrine produced a slight, but significant increase on the QTc interval.(1)

Antimalarials/Halofantrine

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Possibly additive effects on the QTc interval.

CLINICAL EFFECTS: Concurrent use of halofantrine and other antimalarials, such as quinine, chloroquine, or mefloquine, may predispose patients to development of prolonged QTc intervals.(1)

PREDISPOSING FACTORS: The risk of QT prolongation or torsades de pointes may be increased in patients with cardiovascular disease (e.g. heart failure, myocardial infarction, history of torsades de pointes, congenital long QT syndrome), hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, female gender, or advanced age.(5) Concurrent use of more than one drug known to cause QT prolongation or higher systemic concentrations of either QT prolonging drug are additional risk factors for torsades de pointes. Factors which may increase systemic drug concentrations include rapid infusion of an intravenous dose or impaired metabolism or elimination of the drug (e.g. coadministration with an agent which inhibits its metabolism or elimination, genetic impairment in drug metabolism or elimination, and/or renal/hepatic dysfunction).(5)

PATIENT MANAGEMENT: The UK manufacturer of halofantrine states under the contraindications section of the prescribing information that unless there are compelling clinical reasons, halofantrine should not be used with other antimalarials, such as quinine, chloroquine, or mefloquine.(1) The US manufacturer of halofantrine states that halofantrine should not be given with or subsequent to mefloquine.(2) The US manufacturer of mefloquine states that halofantrine must not be given concurrently with or within 15 weeks of the last dose of mefloquine.(3) If concurrent therapy is deemed medically necessary, consider obtaining serum calcium, magnesium, and potassium levels and monitoring ECG at baseline and at regular intervals. Correct any electrolyte abnormalities. Instruct patients to report any irregular heartbeat, dizziness, or fainting.

DISCUSSION: Concurrent halofantrine and mefloquine has been reported to result in further prolongation of the QTc interval.(4) Because concurrent use may predispose patients to prolongation of the QTc interval, the UK manufacturer of halofantrine states under the contraindications section of the prescribing information that halofantrine should not be used with other antimalarials such as quinine, chloroquine, or mefloquine unless compelling clinical reasons exist.(1) The US manufacturer of halofantrine states that halofantrine should not be given with or subsequent to mefloquine.(2) The US manufacturer of mefloquine states that halofantrine must not be given with or subsequent to mefloquine.(3) One or more of the drug pairs linked to this monograph have been included in a list of interactions that should be considered "high-priority" for inclusion and should not be inactivated in EHR systems. This DDI subset was vetted by an expert panel commissioned by the U.S. Office of the National Coordinator (ONC) for Health Information Technology.

Mefloquine/Bcg Vaccines

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Mefloquine may attenuate the immunization response to vaccines with attenuated live bacteria, such as BCG vaccine.(1)

CLINICAL EFFECTS: Concurrent use may make the vaccine ineffective.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of mefloquine states that vaccinations with vaccines containing attenuated live bacteria should be completed three days before the initiation of mefloquine.(1)

DISCUSSION: The manufacturer of mefloquine states that attenuation of immunization response to vaccines with attenuated live bacteria cannot be excluded and therefore the manufacturer of mefloquine states that vaccinations with vaccines containing attenuated live bacteria should be completed three days before the initiation of mefloquine.(1)

Mefloquine/Chloroquine;Hydroxychloroquine;Quinidine;Quinine

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: The exact mechanism is unknown, but may involve additive effects between mefloquine and antimalarials including chloroquine, hydroxychloroquine, quinidine or quinine.

CLINICAL EFFECTS: Concurrent administration of mefloquine with chloroquine, hydroxychloroquine, quinidine or quinine may result in electrocardiographic abnormalities, cardiac arrest, and/or an increased risk of convulsions.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Concurrent use of mefloquine with chloroquine, hydroxychloroquine, quinidine, or quinine is contraindicated. If these agents are used in the initial treatment of malaria, the administration of mefloquine should be delayed until 12 hours after the last dose of chloroquine, hydroxychloroquine, quinidine, or quinine.(1)

DISCUSSION: There is little clinical information to support this interaction. An in vitro study in human liver microsomes showed that quinine inhibits the metabolism of mefloquine.(2) The manufacturer of mefloquine states that concurrent administration of mefloquine with quinine or quinidine may produce electrocardiographic abnormalities or cardiac arrest and that the concurrent administration of mefloquine and quinine or chloroquine may increase the risk of convulsions.(1) The manufacturer of mefloquine states that if quinine or quinidine are used in the treatment of malaria, 12 hours should elapse between the their last dose and the first dose of mefloquine.(1)

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

Selected Cyp3a4 Substrates/Lonafarnib

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Lonafarnib is a strong inhibitor of CYP3A4 and may decrease the metabolism of drugs metabolized by the CYP3A4 enzyme. Lonafarnib is also an inhibitor of P-glycoprotein (P-gp) and may increase the absorption of sirolimus.

CLINICAL EFFECTS: Concurrent use of lonafarnib may lead to increased serum levels and adverse effects of drugs sensitive to inhibition of the CYP3A4 pathway or P-gp.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of lonafarnib states that coadministration of CYP3A4 substrates should be avoided. If concomitant use is unavoidable, monitor for adverse effects and consider dose reduction of the CYP3A4 substrate according to its prescribing information.(1) The manufacturer of lonafarnib states that the dose of P-gp substrates may need to be reduced with coadministration with lonafarnib.(1)

DISCUSSION: In a study of healthy volunteers, lonafarnib (100 mg twice daily for 5 days) increased the area-under-the-curve (AUC) and maximum concentration (Cmax) of a single dose of midazolam (3 mg) by 639% and 180%, respectively.(1) In a study of healthy volunteers, lonafarnib (100 mg twice daily for 5 days) increased the AUC and Cmax of single-dose fexofenadine (180 mg) by 24% and 21%, respectively.(1) CYP3A4 substrates with a narrow therapeutic index linked to this monograph include: bromocriptine, cabergoline, cannabidiol-tetrahydrocannabinol, clonazepam, darolutamide, felodipine, mefloquine, nisoldipine, oliceridine, regorafenib, sirolimus, and zanubrutinib.(1-3)

Slt Antimalarials/Str 3A4 Inducer;Slt Barbiturates,Hydantoin

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Strong CYP3A4 inducers may induce the metabolism of mefloquine, quinidine, and quinine.

CLINICAL EFFECTS: Concurrent use of strong CYP3A4 inducers may result in decreased levels and effectiveness of mefloquine, quinidine, or quinine.

PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks.

PATIENT MANAGEMENT: In patients receiving concurrent strong CYP3A4 inducers, monitor mefloquine, quinidine, or quinine serum levels and observe the patient for symptoms of reduced efficacy. Adjust the dosage accordingly. The US manufacturer of quinine recommends avoiding the concurrent use of rifampin, a strong CYP3A4 inducer, because of the increased risk of malaria treatment failure.

DISCUSSION: Several studies document the reduction in quinidine response in patients receiving concurrent rifampin. Decreased elimination half-life, reduced area-under-curve (AUC), and low serum quinidine level were observed. In healthy volunteers, quinine AUC and maximum concentration (Cmax) were reduced 85% and 55%, respectively, after a single dose of rifampin was added after two weeks of quinine therapy.(6) In a randomized control trial of 59 male patients with Plasmodium falciparum malaria, treatment with concomitant quinine and rifampin was associated with a cure rate of only 35% compared to 88% in those treated with quinine monotherapy. The AUC of quinine during treatment days 3 through 7 was significantly reduced in the quinine plus rifampin group compared to those treated with quinine alone (11.7 vs. 47.5 mcg/ml/day; p < 0.004).(7) In an open-label, cross-over study in 7 healthy subjects, concurrent rifampin (600 mg daily) decreased the AUC and Cmax of a single dose of mefloquine (500 mg) by 68% and 19%, respectively.(8,9) Agents linked to this monograph include: apalutamide, barbiturates, carbamazepine, enzalutamide, ethotoin, fosphenytoin, lumacaftor, mitotane, natisedine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentine, and St. John's wort.(10)

Moderate Interaction: Assess the risk to the patient and take action as needed.

Mefloquine/Selected Strong Cyp3a4 Inhibitors;Protease Inhib

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Inhibitors of CYP3A4 may inhibit the metabolism of mefloquine.(1)

CLINICAL EFFECTS: Concurrent use of strong CYP3A4 inhibitors or protease inhibitors with mefloquine may result in elevated levels of mefloquine and toxicity.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of mefloquine states that concurrent use with strong CYP3A4 inhibitors should be approached with caution.(1) The US Department of Health and Human Services HIV guidelines recommend considering alternative therapies to protease inhibitors or monitoring for adverse events and virologic response.(2)

DISCUSSION: In a study in 8 healthy subjects, administration of ketoconazole (400 mg daily) for 10 days followed by a single 500 mg dose of mefloquine resulted in an increase in the AUC of mefloquine by 79%. The elimination half-life was increased from 322 hours to 448 hours.(1) Strong CYP3A4 inhibitors and protease inhibitors linked to this monograph include: adagrasib, atazanavir, boceprevir, ceritinib, clarithromycin, cobicistat, darunavir, ensitrelvir, fosamprenavir, idelalisib, indinavir, itraconazole, josamycin, ketoconazole, levoketoconazole, mibefradil, mifepristone, nefazodone, nelfinavir, nirmatrelvir/ritonavir, paritaprevir, posaconazole, relacorilant, ribociclib, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, tucatinib, and voriconazole.(3,4)

Mefloquine/Typhoid Vaccine Live Attenuated

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Mefloquine may attenuate the immunization response to vaccines with attenuated live bacteria.(1)

CLINICAL EFFECTS: Concurrent use may make the vaccine ineffective.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of mefloquine states that administration of vaccines which contain attenuated live bacteria should be completed three days before the initiation of mefloquine.(1) To optimize vaccine effectiveness, the Centers for Disease Control(CDC) recommends, when feasible, delay of antibacterial drug therapy for one week after the last dose of oral typhoid vaccine.(2) The manufacturer of oral typhoid Ty21a vaccine states concomitant treatment with mefloquine does not significantly reduce immune response rate.(3)

DISCUSSION: The manufacturer of mefloquine states that attenuation of immunization response to vaccines with attenuated live bacteria cannot be excluded and therefore the manufacturer of mefloquine states that vaccinations with vaccines containing attenuated live bacteria should be completed three days before the initiation of mefloquine.(1)

Mefloquine; Quinidine/Beta-Blockers

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Quinidine may inhibit the oxidative metabolism of beta-blockers. In addition, beta-blockers and quinidine exert a negative inotropic action on the heart. Mefloquine is a chemical analogue of quinine which possess 20% of the antifibrillatory action of quinidine. Alterations in electrocardiograms have been observed during mefloquine therapy.

CLINICAL EFFECTS: The pharmacologic effects of certain beta-blockers may be increased during concurrent therapy with quinidine. During concurrent therapy with mefloquine, electrocardiographic abnormalities or cardiac arrest may occur.

PREDISPOSING FACTORS: Cardiac disease.

PATIENT MANAGEMENT: Monitor the response of the patient and adjust the dose of the beta-blocker as needed. The benefits of mefloquine therapy in patients with preexisting cardiac disease should be weighed carefully.

DISCUSSION: Quinidine and beta-blockers have been used therapeutically to treat cardiac arrhythmias; however, they should be used cautiously since quinidine and beta-blockers exert a negative inotropic action on the heart. Quinidine has been associated with an increase in serum metoprolol levels. A reduction in propranolol clearance has been demonstrated in one study, although others have failed to show an interaction between propranolol and quinidine. A patient using timolol eyedrops developed bradycardia following administration of quinidine. There is one report of cardiac arrest, which was successfully treated, in a patient receiving concurrent mefloquine and propranolol. The manufacturer of mefloquine states that concurrent use may produce electrocardiographic abnormalities and cardiac arrest. The manufacturer also recommends weighing the benefits of mefloquine therapy against the risk of adverse effects in patients with cardiac disease.

There is no enhanced messaging for this drug.

• Depression
• Generalized anxiety disorder
• Psychotic disorder
• Schizophrenia
• Seizure disorder

• Sinus bradycardia

• Ataxia
• Atrioventricular block
• Disease of liver
• Myasthenia gravis
• Prolonged QT interval
• Sinus node dysfunction

There is no enhanced messaging for this drug.

More Frequent

• Concentration difficulty

Less Frequent

• Dyspnea

Rare or Very Rare

• Abnormal hepatic function tests
• Acute cognitive impairment
• Agranulocytosis
• Anaphylaxis
• Aplastic anemia
• Ataxia
• Bradycardia
• Cardiac arrest
• Cardiac arrhythmia
• Depression
• Drug-induced psychosis
• Encephalopathy
• Erythema multiforme
• Hallucinations
• Hepatic failure
• Hypersensitivity pneumonitis
• Hypertension
• Hypotension
• Leukocytosis
• Mood changes
• Muscle weakness
• Nervousness
• Panic disorder
• Paranoid disorder
• Paresthesia
• Prolonged QT interval
• Seizure disorder
• Stevens-johnson syndrome
• Suicidal
• Suicidal ideation
• Syncope
• Thrombocytopenic disorder
• Tremor
• Urticaria
• Vertigo

More Frequent

• Abdominal pain with cramps
• Anorexia
• Diarrhea
• Dizziness
• Headache disorder
• Insomnia
• Nausea
• Visual changes
• Vomiting

Less Frequent

• Fatigue
• Myalgia
• Skin rash

Rare or Very Rare

• Alopecia
• Arthralgia
• Behavioral disorders
• Chills
• Cramps
• Dream disorder
• Dyspepsia
• Edema
• Erythema
• Fever
• General weakness
• Hyperhidrosis
• Malaise
• Memory impairment
• Polyneuropathy
• Pruritus of skin
• Symptoms of anxiety
• Tinnitus

No enhanced messaging available.

No enhanced messaging available.

The manufacturer states that mefloquine should be used during pregnancy only when clearly needed and that women of childbearing potential should be advised to use effective contraceptive measures while receiving mefloquine and for up to 3 months after the last dose of the drug.

The CDC and American Academy of Pediatrics (AAP) state that mefloquine is the drug of choice for prevention of malaria in women who are pregnant, or likely to become pregnant, if exposure to chloroquine-resistant P. falciparum is unavoidable. In addition, the CDC states that mefloquine is a drug of choice for the treatment of uncomplicated malaria caused by chloroquine-resistant P. falciparum or chloroquine-resistant P. vivax in pregnant women. (See Uses: Malaria.)

Published data on use of mefloquine for prevention or treatment of malaria during pregnancy, including data from randomized controlled trials, intervention trials, prospective and retrospective cohort studies, and case series, have not shown an increased risk of teratogenic effects or adverse pregnancy outcomes compared to the background rate in the general population. These data include more than 700 exposures to mefloquine in the first trimester of pregnancy and over 2,000 exposures in the second and third trimesters. However, mefloquine was teratogenic in mice, rats, and rabbits when given in dosages that were similar to those used for the treatment of malaria (based on body surface area comparisons). CNS effects (e.g., exencephaly, hydrocephaly, partially missing medulla oblongata) and craniofacial malformations were observed in all 3 species. Mefloquine also was embryotoxic in mice and rabbits at these dosages.

Adverse fetal or pregnancy outcomes were not indicated in a double-blind study and clinical experience that included women who received mefloquine during the second and third trimesters. In addition, the frequencies of spontaneous abortion and congenital malformations in 1133 women exposed to mefloquine during the first trimester of pregnancy (more than 95% received mefloquine for prophylaxis) were within expected background rates, and the abnormalities did not fit a specific pattern and would be difficult to attribute to a single pathogenic mechanism. Data from a study evaluating the relationship between use of mefloquine for the treatment of malaria during pregnancy and pregnancy outcome indicate that mefloquine exposure during pregnancy was not associated with an increased incidence of abortion, low birthweight, neurologic retardation, or congenital malformations; however, mefloquine exposure was associated with a greater risk of stillbirth than exposure to other antimalarials, including quinine.

Small amounts of mefloquine are distributed into breast milk. In one study in a limited number of women, approximately 3-4% of a single 250-mg mefloquine dose was distributed into breast milk. Following administration of a single 250-mg dose of the drug in one woman, mefloquine concentrations in breast milk at 4 and 56 days were 53 and 32 ng/mL, respectively.

The manufacturer states that mefloquine should be used with caution in nursing women. Because the amount of mefloquine consumed by a nursing infant is likely to be small, some clinicians suggest that the risk to nursing infants of maternal use of prophylactic dosages of mefloquine is low. However, the amount of mefloquine present in breast milk is insufficient to provide adequate protection against malaria in the nursing infant and, if chemoprophylaxis is necessary, such infants should receive recommended dosages of an appropriate antimalarial.

No enhanced messaging available.